Answers are grounded in this paper and cite their sources.
Objective: To estimate the equivalent radiation dose in 2 Gy fractions (EQD2Gy) and tumour control probability (TCP) from probe based and magnetic resonance (MR) temperature measurements. In addition, we evaluate how uncertainties in MR thermometry affect these metrics in combined radiotherapy and hyperthermia for locally advanced cervical cancer (LACC). Approach: Temperature data were collected from three patients with LACC treated with radiotherapy and MR guided deep hyperthermia (MRgHT). Intraluminal vaginal probes provided temperature measurements at surrogate locations, while MR thermometry enabled voxel-wise temperature mapping within the target volume. These data were used to estimate EQD2Gy and TCP for combined radiotherapy and hyperthermia treatments. To assess the robustness of MR-based estimates, systematic and random temperature errors were introduced into MR thermometry data using Gaussian error models to simulate artefacts. The resulting impact on temperature distributions, EQD2Gy and TCP was evaluated using standard deviation analysis and dose volume histograms. Main results: Probe-based temperatures ranged from 39.1-39.7 °C, resulting in EQD2Gy and TCP enhancements of 2.4-4.3 Gy and 20-57 %, respectively. MR-based temperatures were higher (39.4-40.3 °C), yielding EQD2Gy (3.4-7.1 Gy) and TCP (22–68 %). Systematic temperature errors produced changes of up to 2 Gy in EQD2Gy and 5 % in TCP. In contrast, random errors - more representative of typical MR thermometry artefacts - led to minimal deviations, with changes of approximately 0.2 Gy in EQD2Gy. Within clinically relevant temperature ranges, overall uncertainties remained limited to 0.7 Gy for EQD2Gy and 1 % for TCP. Significance: MR thermometry enables voxel-based estimation of biological treatment enhancement in combined radiotherapy and hyperthermia. Despite inherent temperature uncertainties, MR-based EQD2Gy and TCP estimates remain robust within clinical accuracy limits, supporting their use for treatment evaluation and future hyperthermia-informed treatment planning.
No takes yet. Share an insight, caveat, or question.
Carrapiço-Seabra et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: